Telix Pharmaceuticals Limited reported that the Phase 2 OPTIMAL‑PSMA trial of its PSMA‑targeting radioligand therapy TLX597‑Tx produced encouraging dosimetry data. The study enrolled 120 men with metastatic castration‑resistant prostate cancer and used an intensified dosing schedule of 8.5 GBq on days 1, 3 and 15, followed by weekly dosing for three additional cycles. The results showed a highly favorable radiation dose profile, with significantly reduced exposure to healthy organs such as the salivary glands and kidneys compared with existing PSMA radioligand therapies, while achieving higher tumor uptake and a wider therapeutic window.
The trial’s dosimetry data were presented at the 2026 International Prostate Cancer Symposium in Lugano, Switzerland, on April 29, 2026, and the announcement was made the following day. Telix’s Group Chief Medical Officer, Dr. David N. Cade, said, "These encouraging dosimetry results from OPTIMAL‑PSMA, combined with earlier exploratory work, are very promising and highlight TLX597‑Tx's potential to substantially increase the tumor dose while minimizing radiation to sensitive organs."
The findings support further evaluation of TLX597‑Tx in earlier‑stage disease and justify the initiation of a Phase 2 OPTIMAL‑E study in hormone‑sensitive prostate cancer. Professor Louise Emmett, Principal Investigator for OPTIMAL‑PSMA, commented, "The goal of OPTIMAL‑PSMA is to identify a dose regimen for TLX597‑Tx that leads to deeper and longer responses without increasing toxicity for men with metastatic prostate cancer. We look forward to starting the Phase 2 OPTIMAL‑E trial soon."
Telix’s strategy of pairing diagnostic imaging with targeted therapy is reinforced by these results, positioning the company to personalize treatment and minimize quality‑of‑life side effects. The trial also strengthens Telix’s dual prostate cancer pipeline, which includes the phase 3 TLX591‑Tx for metastatic castration‑resistant disease and the phase 2 TLX597‑Tx for earlier‑stage disease. By demonstrating improved dosimetry relative to the FDA‑approved 177Lu‑PSMA‑617, TLX597‑Tx could carve out a competitive niche in the growing PSMA‑targeted radioligand market.
Financially, Telix reported Q1 2026 revenue of $230 million, up 24% year‑over‑year, and reaffirmed its FY 2026 revenue guidance at $950–$970 million. The strong revenue growth provides the financial foundation to continue investing in its pipeline, including the OPTIMAL‑PSMA and upcoming OPTIMAL‑E trials. The positive dosimetry data, combined with robust financial performance, signals confidence in Telix’s ability to advance its therapeutic candidates and capture market share in the prostate cancer space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.